Arzerra Related Published Studies
Well-designed clinical trials related to Arzerra (Ofatumumab)
Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive,
rheumatoid arthritis patients with an inadequate response to methotrexate: a
randomised, double-blind, placebo-controlled clinical trial. [2011]
Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. [2010.08]
Well-designed clinical trials possibly related to Arzerra (Ofatumumab)
Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. [2011.06.16]
Other research related to Arzerra (Ofatumumab)
Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic
lymphocytic leukaemia. [2012]
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from
a multicenter study. [2012]
Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. [2011.12]
Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. [2011.11.10]
Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia. [2011.10]
Ofatumumab in the treatment of low-grade non-Hodgkin's lymphomas and chronic lymphocytic leukemia. [2011.05]
The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia. [2011.03.24]
Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia. [2011.02]
Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia. [2010.10]
U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. [2010.09.01]
Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. [2010.07.20]
Ofatumumab in the treatment of chronic lymphocytic leukemia. [2010.07]
Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 study. [2010.07]
Ofatumumab. [2010.05.28]
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. [2010.04.01]
Ofatumumab, a human anti-CD20 monoclonal antibody. [2010.03]
The European Medicines Agency review of ofatumumab (Arzerra(R)) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: summary of the scientific assessment of the European medicines agency committee for medicinal products for human use. [2010]
Ofatumumab. [2009.07]
Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. [2009.07]
Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. [2009.04]
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. [2008.06.15]
Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders. [2008.06]
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. [2008.02.01]
Other possibly related research studies
Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options. [2010.07]
Chronic lymphocytic leukemia: putting new treatment options into perspective. [2010.04]
New agents in chronic lymphocytic leukemia. [2010.01]
Treating multiple sclerosis with monoclonal antibodies: a 2010 update. [2010.05]
The future of CD20 monoclonal antibody therapy in B-cell malignancies. [2010.06]
CD20-targeted therapy: the next generation of antibodies. [2010.04]
Specific immune intervention with monoclonal antibodies for the treatment of multiple sclerosis. [2010]
Modern concepts in the treatment of chronic lymphocytic leukemia. [2009.10]
Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity. [2009.12]
Update in the management of chronic lymphocytic leukemia. [2009.07.20]
[Novel B-cell directed strategies for the treatment of rheumatic diseases] [2009.07]
Targeted therapy for chronic lymphocytic leukemia. [2009.01]
Prospective new biological therapies for rheumatoid arthritis. [2009.12]
Monoclonal antibodies in the treatment of systemic lupus erythematosus. [2009.01]
Emerging therapeutics for rheumatoid arthritis. [2008]
Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma. [2008.10]
Novel human antibody therapeutics: the age of the Umabs. [2008.10]
Newer monoclonal antibodies for hematological malignancies. [2008.07]
[Biological treatment of multiple sclerosis] [2008.06.09]
New approaches of B-cell-directed therapy: beyond rituximab. [2008.05]
Antibody therapy for chronic lymphocytic leukemia. [2008.04]
Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia. [2008.03]
Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. [2008.02]
Gateways to clinical trials. [2007.10]
Mechanisms of killing by anti-CD20 monoclonal antibodies. [2007.09]
Gateways to clinical trials. [2007.04]
Bendamustine's emerging role in the management of lymphoid malignancies. [2011.04]
Bendamustine therapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia. [2011.02]
New therapies in the management of rheumatoid arthritis. [2011.05]
Cancer immunotherapy. [2011.02]
Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly. [2011.03.01]
Novel agents for the treatment of chronic lymphocytic leukemia. [2010.12]
Refractory chronic lymphocytic leukemia--new therapeutic strategies. [2010.11]
gammadelta T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody. [2011.03]
State of the art treatment of chronic lymphocytic leukaemia. [2011.01]
New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. [2011.02.01]
Follicular lymphoma: emerging therapeutic strategies. [2010.08]
Development trends for human monoclonal antibody therapeutics. [2010.10]
Therapeutic options for HIV-associated lymphomas. [2010.10]
Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy. [2010.05]
Monoclonal antibody therapy of chronic lymphocytic leukaemia. [2010.03]
The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. [2010.11.11]
How I treat elderly or comorbid patients with chronic lymphocytic leukemia. [2010]
|
